CG Oncology officer plans 10,551-share stock sale

Rhea-AI Filing Summary

CG Oncology, Inc. (CGON) received a notice under Rule 144 from officer Ambaw Bellete covering proposed sales of common stock. The notice lists a planned sale of 10,551 shares of common stock to be sold for cash on or about August 25, 2026, following a stock option exercise. It also details multiple prior sales of CGON common shares by Bellete over the past three months, including several large transactions in July and August 2026.

Key Figures

Shares to be sold: 10,551 shares Aggregate market value of planned sale: $839,338.38 Approximate date of sale: 08/25/2026 +3 more

6 metrics

Shares to be sold 10,551 shares Common stock covered by the planned Rule 144 sale

Aggregate market value of planned sale $839,338.38 Value associated with 10,551 shares of CG Oncology common stock

Approximate date of sale 08/25/2026 Intended sale date for 10,551 shares under Form 144

Prior sale on 08/19/2026 100,000 shares for $7,954,105.00 Common stock sale by Ambaw Bellete during the past three months

Prior sale on 08/06/2026 75,000 shares for $5,672,212.50 Common stock sale by Ambaw Bellete during the past three months

Prior sale on 07/15/2026 52,438 shares for $3,816,007.65 Common stock sale by Ambaw Bellete during the past three months

Key Terms

Rule 144, Stock Option Exercise, Form 144, aggregate market value

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"Common | 08/25/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

aggregate market value financial

"| 10551 | 839338.38 | 88640375 | 08/25/2026 |"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

What does CGON’s Form 144 filed by Ambaw Bellete disclose?

The Form 144 for CGON discloses that officer Ambaw Bellete intends to sell 10,551 shares of CG Oncology common stock on or about August 25, 2026, in connection with a stock option exercise, and lists prior sales made in the last three months.

How many CGON shares does Ambaw Bellete plan to sell under this Form 144?

Ambaw Bellete plans to sell 10,551 shares of CG Oncology, Inc. common stock. The Form 144 identifies these shares as being related to a stock option exercise and indicates the intended sale date as August 25, 2026 for a cash transaction.

What is the reported market value of the CGON shares covered by the planned sale?

The Form 144 reports that the 10,551 shares of CG Oncology common stock subject to the planned sale have an aggregate market value of approximately $839,338.38, based on the pricing information provided in the securities section for this planned transaction.

What past CGON stock sales by Ambaw Bellete are listed in the last three months?

The filing lists multiple past sales of CG Oncology common stock by Ambaw Bellete, including a sale of 100,000 shares for $7,954,105.00 on August 19, 2026 and several other transactions in August and July 2026, each with specified share counts and dollar amounts.

On which market is CG Oncology (CGON) common stock listed in this filing?

The Form 144 states that CG Oncology, Inc. common stock is traded on NASDAQ. This designation appears in the securities information section describing the common shares that are the subject of Ambaw Bellete’s planned sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/25/2026 - 04:38 PM Accepted by SEC EDGAR 08/25/2026 - 04:38 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002007090
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CG ONCOLOGY, INC.
SEC File Number	001-41925
Address of Issuer	3000 Pegasus Park Drive SUITE 1640 Dallas TEXAS 75247
Phone	(949) 409-3700
Name of Person for Whose Account the Securities are To Be Sold	AMBAW BELLETE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	10551	839338.38	88640375	08/25/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/25/2026	Stock Option Exercise	Issuer			10551	08/25/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/24/2026	5762	458185.02
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/19/2026	100000	7954105.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/17/2026	52438	4034894.35
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/14/2026	19364	1452635.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/13/2026	25989	1973970.86
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/12/2026	32137	2526514.53
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/11/2026	50000	3810255.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/10/2026	50000	3770580.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/07/2026	9250	696062.50
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/06/2026	75000	5672212.50
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	08/05/2026	25000	1837500.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/29/2026	4303	316270.50
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/28/2026	50000	3625195.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/27/2026	50000	3627995.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/23/2026	50000	3588620.00
AMBAW BELLETE 3000 Pegasus Park Drive SUITE 1640 Dallas TX 75247	Common	07/15/2026	52438	3816007.65

144: Remarks and Signature

Remarks
Date of Notice	08/25/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Ambaw Bellete
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)